Skip to main content
Moderna, Inc. (MRNA)
NASDAQ: MRNA · Real-Time Price · USD
26.89
+1.23 (4.79%)
At close: Aug 13, 2025, 4:00 PM
26.99
+0.10 (0.37%)
Pre-market: Aug 14, 2025, 8:02 AM EDT

Moderna Revenue by Segment
Period Ending Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020
Product Sales
3.03B 3.11B 4.96B 4.90B 5.01B 6.67B 8.77B 10.14B
Product Sales Growth
-39.56% -53.40% -43.42% -51.65% -65.15% -63.88% -57.23% -54.34%
Grant and Collaboration
149.00M 127.00M 117.00M 149.00M - 177.00M 384.00M 554.00M
Grant and Collaboration Growth
- -28.25% -69.53% -73.10% - -78.62% -56.31% -30.23%

Product Sales by Geography
Period Ending Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022
United States
1.66B 1.73B 2.28B 1.98B 1.82B 1.72B 1.94B 2.01B
United States Growth
-8.91% 0.35% 17.52% -1.69% -47.44% -60.95% - -
Rest of World
798.00M 810.00M 1.79B 2.21B 2.41B 3.60B 3.84B 4.19B
Rest of World Growth
-66.94% -77.49% -53.39% -47.31% -57.24% -50.70% - -
Europe
- 573.00M 895.00M - - 1.35B 2.96B 3.90B
Europe Growth
- -57.65% -69.76% - - -79.90% - -

Operating Expense Breakdown
Period Ending Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020
Research and Development
4.34B 4.54B 4.83B 4.85B 4.78B 4.85B 4.65B 4.31B
Research and Development Growth
-9.23% -6.23% 3.81% 12.53% 23.37% 47.04% 70.20% 77.15%
Selling, General, and Administrative
1.11B 1.17B 1.29B 1.45B 1.52B 1.55B 1.45B 1.29B
Selling, General, and Administrative Growth
-26.75% -24.21% -11.07% 12.71% 29.85% 36.84% 51.77% 52.12%
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.